Man Group
EGRX

Man Group’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Man Group’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-105,221
Closed -$551K – 2328
2024
Q1 		$551K Buy
105,221
+43,677
+71% +$240K ﹤0.01% 1750
2023
Q4 		$322K Buy
+61,544
New +$608K ﹤0.01% 1799
2023
Q3 		– Hold
0
– – – 1474
2022
Q4 		– Sell
-68,686
Closed -$1.81M – 2289
2022
Q3 		$1.81M Buy
+68,686
New +$2.52M 0.01% 1100
2022
Q2 		– Sell
-139,273
Closed -$6.4M – 801
2022
Q1 		$6.89M Sell
139,273
-7,200
-5% -$346K 0.02% 760
2021
Q4 		$7.46M Buy
146,473
+12,700
+9% +$658K 0.02% 715
2021
Q3 		$7.46M Sell
133,773
-4,100
-3% -$202K 0.03% 683
2021
Q2 		$5.9M Sell
137,873
-4,800
-3% -$198K 0.02% 813
2021
Q1 		$5.96M Buy
142,673
+40,553
+40% +$1.88M 0.03% 613
2020
Q4 		$4.76M Sell
102,120
-21,800
-18% -$1.02M 0.02% 839
2020
Q3 		$5.26M Buy
123,920
+56,833
+85% +$2.49M 0.02% 785
2020
Q2 		$3.22M Sell
67,087
-1,605
-2% -$80.1K 0.02% 868
2020
Q1 		$3.16M Sell
68,692
-16,566
-19% -$831K 0.02% 686
2019
Q4 		$5.12M Sell
85,258
-21,364
-20% -$1.27M 0.02% 989
2019
Q3 		$6.03M Sell
106,622
-29,613
-22% -$1.67M 0.02% 791
2019
Q2 		$7.59M Buy
136,235
+120,835
+785% +$6.3M 0.03% 762
2019
Q1 		$778K Buy
+15,400
New +$685K ﹤0.01% 1642
2018
Q4 		– Sell
-4,769
Closed -$331K – 2156
2018
Q3 		$331K Buy
+4,769
New +$362K ﹤0.01% 1925

Other funds holding EGRX

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Man Group's EGRX Position: Q2 2024 in Review

Man Group sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2024, closing a stake of 105,221 shares — an estimated $551K sold.

Man Group first reported a position in EGRX in Q3 2018 and held it in 17 quarters. The position peaked at $7.59M in Q2 2019. 75 funds tracked by Wall St. Rank hold EGRX as of Q2 2024.

  • Man Group reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
  • Man Group sold 105,221 Eagle Pharmaceuticals, Inc. shares in Q2 2024, an estimated $551K.
  • Man Group first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2018 and held it in 17 quarters.
  • Man Group's Eagle Pharmaceuticals, Inc. position peaked at $7.59M in Q2 2019.
  • 75 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2024.

Based on Man Group's 13F filing for Q2 2024, filed 14 Aug 2024.